» Articles » PMID: 25478571

Cellular Levels of Oxidative Stress Affect the Response of Cervical Cancer Cells to Chemotherapeutic Agents

Overview
Journal Biomed Res Int
Publisher Wiley
Date 2014 Dec 6
PMID 25478571
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

Treatment of advanced and relapsed cervical cancer is frequently ineffective, due in large part to chemoresistance. To examine the pathways responsible, we employed the cervical carcinoma-derived SiHa and CaSki cells as cellular models of resistance and sensitivity, respectively, to treatment with chemotherapeutic agents, doxorubicin, and cisplatin. We compared the proteomic profiles of SiHa and CaSki cells and identified pathways with the potential to contribute to the differential response. We then extended these findings by comparing the expression level of genes involved in reactive oxygen species (ROS) metabolism through the use of a RT-PCR array. The analyses demonstrated that the resistant SiHa cells expressed higher levels of antioxidant enzymes. Decreasing or increasing oxidative stress led to protection or sensitization, respectively, in both cell lines, supporting the idea that cellular levels of oxidative stress affect responsiveness to treatment. Interestingly, doxorubicin and cisplatin induced different profiles of ROS, and these differences appear to contribute to the sensitivity to treatment displayed by cervical cancer cells. Overall, our findings demonstrate that cervical cancer cells display variable profiles with respect to their redox-generating and -adaptive systems, and that these different profiles have the potential to contribute to their responses to treatments with chemotherapy.

Citing Articles

Synergistic celecoxib and dimethyl-celecoxib combinations block cervix cancer growth through multiple mechanisms.

Robledo-Cadena D, Pacheco-Velazquez S, Vargas-Navarro J, Padilla-Flores J, Lopez-Marure R, Perez-Torres I PLoS One. 2024; 19(9):e0308233.

PMID: 39325741 PMC: 11426494. DOI: 10.1371/journal.pone.0308233.


Oxidative Stress Inducers in Cancer Therapy: Preclinical and Clinical Evidence.

Nizami Z, Aburawi H, Semlali A, Muhammad K, Iratni R Antioxidants (Basel). 2023; 12(6).

PMID: 37371889 PMC: 10295724. DOI: 10.3390/antiox12061159.


Comparative Anticancer Study of Cisplatin Drug with Green Synthesized ZnO Nanoparticles on Cervical Squamous Carcinoma (SiHa) Cell Lines.

Rani N, Rawat K, Saini M, Yadav S, Syeda S, Saini K ACS Omega. 2023; 8(16):14509-14519.

PMID: 37125098 PMC: 10134227. DOI: 10.1021/acsomega.2c08302.


Doxorubicin-An Agent with Multiple Mechanisms of Anticancer Activity.

Kciuk M, Gielecinska A, Mujwar S, Kolat D, Kaluzinska-Kolat Z, Celik I Cells. 2023; 12(4).

PMID: 36831326 PMC: 9954613. DOI: 10.3390/cells12040659.


Gene Promoter-Methylation Signature as Biomarker to Predict Cisplatin-Radiotherapy Sensitivity in Locally Advanced Cervical Cancer.

Contreras-Romero C, Perez-Yepez E, Martinez-Gutierrez A, Campos-Parra A, Zentella-Dehesa A, Jacobo-Herrera N Front Oncol. 2022; 12:773438.

PMID: 35359376 PMC: 8963763. DOI: 10.3389/fonc.2022.773438.


References
1.
Liang X, Mungal S, Ayscue A, Meissner J, Wodnicki P, Hockenbery D . Bcl-2 protooncogene expression in cervical carcinoma cell lines containing inactive p53. J Cell Biochem. 1995; 57(3):509-21. DOI: 10.1002/jcb.240570316. View

2.
Banerjee S, Fallis A, Brown D . Differential effects of taxol on two human cancer cell lines. Oncol Res. 1997; 9(5):237-48. View

3.
Martasek P, Hogg N, Masters B, Pritchard Jr K, Kalyanaraman B . Endothelial nitric oxide synthase-dependent superoxide generation from adriamycin. Biochemistry. 1997; 36(38):11293-7. DOI: 10.1021/bi971475e. View

4.
Anderson M . Glutathione: an overview of biosynthesis and modulation. Chem Biol Interact. 1998; 111-112:1-14. DOI: 10.1016/s0009-2797(97)00146-4. View

5.
Zhou P, Kalakonda N, Comenzo R . Changes in gene expression profiles of multiple myeloma cells induced by arsenic trioxide (ATO): possible mechanisms to explain ATO resistance in vivo. Br J Haematol. 2005; 128(5):636-44. DOI: 10.1111/j.1365-2141.2005.05369.x. View